It was determined that the pH-sensitive strategy to release the CD44 inhibitor from the nanodevice at the acidic tumor microenviroment enhanced the efficient interaction with the CD44 receptor and significantly reduced HA binding. The gene discussed is CD44; the disease is neoplasm.